Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. They correspond to U.K.'s short-acting psychedelic therapies developer Small Pharma's (OTC:DMTTF) open-label Phase 1b study assessing the joint work of its "native" DMT compound, SPL026 and selective serotonin reuptake inhibitors (SSRIs.) Read more HERE. Canadian Practitioners Can Now Enroll In MDMA-Assisted Psychotherapy Training Program, Legal Medical Psilocybin Access For Veteran Approved Canadian not
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Benzinga · 10/02/2023 21:46
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.